

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners. [Privacy-Statement](#)

> [Cookie Settings](#)

✓ [Accept Cookies](#)

05-02-2020 | Children | News

One in 300 young children may have presymptomatic type 1 diabetes


medwireNews: Around one in 300 children aged 2–5 years from the general population may be positive for islet autoantibodies on screening and therefore have presymptomatic type 1 diabetes, results of the Fr1da study suggest.

The findings are based on an analysis of data for 90,632 children from Bavaria in Germany who took part in a public health screening program between 2015 and 2019.

In all, 280 (0.31%) children were positive for two or more islet autoantibodies, including 196 (0.22%) with stage 1 diabetes (normoglycemia), 17 (0.02%) with stage 2 diabetes (dysglycemia), and 26 (0.03%) with stage 3 diabetes (clinical). The remaining 41 children had no staging information.

During a mean 2.4 years of follow-up, a further 36 (0.04%) children developed stage 3 type 1 diabetes, and the 3-year cumulative risk for this outcome among the 280 islet autoantibody-positive children was 24.9%, corresponding to an annualized rate of 9.0%.

Anette-Gabriele Ziegler (Helmholtz Zentrum München, Germany) and colleagues report that children were significantly more likely to have presymptomatic type 1 diabetes if they had a first-degree relative with type 1 diabetes (adjusted relative risk [aRR]=3.69), were obese (aRR=1.77), and were aged 4 (RR=1.50) or 5 years (RR=1.86) compared with aged 3 years and younger.

In addition, the risk for clinical type 1 diabetes was significantly higher among children with four versus two autoantibodies (hazard ratio [HR]=1.85) and among those whose screening results were positive for IA-2A (HR=3.40). By contrast, children with  versus without GADA had a significantly lower risk

Just two (3.2%) of the 62 children with clinical diabetic ketoacidosis, which the researchers reported prevalence rates among unscreened (40%).

Ziegler and team also assessed parental psych using the Patient Health Questionnaire-9 and

Welcome to Medicine Matters! We're working to provide you with a better browsing experience. Help us by letting us know if you're a healthcare professional.

Yes

No

Next

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners. [Privacy-Statement](#)

> [Cookie Settings](#)

✓ [Accept Cookies](#)

Writing in *JAMA*, Ziegler and co-authors conclude that their study “provides information on evaluating whether public health screening might eventually be of value in some populations.”

But they add that “a randomized clinical trial would be required to assess whether screening reduces diabetic ketoacidosis or affects psychological stress.”

The investigators also suggest that primary care screening “could rapidly disseminate access to therapies” for children with stage 2 diabetes who may benefit from a single 14-day course of teplizumab to delay progression to stage 3.

By Laura Cowen

medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature group

JAMA 2020; **323** : 339–351

Welcome to Medicine Matters! We're working to provide you with a better browsing experience. Help us by letting us know if you're a healthcare professional.

Yes

No

Next